Edward Handelsman
Overview
Explore the profile of Edward Handelsman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
778
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nachman S, Alvero C, Acosta E, Teppler H, Homony B, Graham B, et al.
J Pediatric Infect Dis Soc
. 2015 Nov;
4(4):e76-83.
PMID: 26582887
Background: IMPAACT P1066 is a Phase I/II open-label multicenter trial to evaluate safety, tolerability, pharmacokinetics (PK), and efficacy of multiple raltegravir (RAL) formulations in human immunodeficiency virus (HIV)-infected youth. Methods:...
2.
Clarke D, Acosta E, Rizk M, Bryson Y, Spector S, Mofenson L, et al.
J Acquir Immune Defic Syndr
. 2014 Aug;
67(3):310-5.
PMID: 25162819
: International Maternal Pediatric Adolescent AIDS Clinical Trials P1097 was a multicenter trial to determine washout pharmacokinetics and safety of in utero/intrapartum exposure to raltegravir in infants born to HIV-infected...
3.
Siberry G, Abzug M, Nachman S, Brady M, Dominguez K, Handelsman E, et al.
Pediatr Infect Dis J
. 2014 Feb;
32 Suppl 2:i-KK4.
PMID: 24569199
No abstract available.
4.
Cotton M, Violari A, Otwombe K, Panchia R, Dobbels E, Rabie H, et al.
Lancet
. 2013 Nov;
382(9904):1555-63.
PMID: 24209829
Background: Interim results from the children with HIV early antiretroviral (CHER) trial showed that early antiretroviral therapy (ART) was life-saving for infants infected with HIV. In view of the few...
5.
Nachman S, Zheng N, Acosta E, Teppler H, Homony B, Graham B, et al.
Clin Infect Dis
. 2013 Oct;
58(3):413-22.
PMID: 24145879
Background: IMPAACT P1066 is a phase I/II open-label multicenter trial to evaluate pharmacokinetics, safety, tolerability, and efficacy of multiple raltegravir formulations in human immunodeficiency virus (HIV)-infected youth. Methods: Dose selection...
6.
Abzug M, Nachman S, Muresan P, Handelsman E, Watts D, Fenton T, et al.
Clin Infect Dis
. 2013 Feb;
56(10):1488-97.
PMID: 23378284
Background: Pregnant women infected with human immunodeficiency virus (HIV) may have particular vulnerability to 2009 pandemic H1N1 influenza (pH1N1) infection. The safety and immunogenicity of pH1N1 vaccination in HIV-infected pregnant...
7.
Weinberg A, Muresan P, Fenton T, Richardson K, Dominguez T, Bloom A, et al.
Hum Vaccin Immunother
. 2013 Feb;
9(5):957-68.
PMID: 23370281
HIV-infected individuals have poor responses to inactivated influenza vaccines. To evaluate the potential role of regulatory T (Treg) and B cells (Breg), we analyzed their correlation with humoral and cell-mediated...
8.
Flynn P, Nachman S, Muresan P, Fenton T, Spector S, Cunningham C, et al.
J Infect Dis
. 2012 May;
206(3):421-30.
PMID: 22615311
Background: The safety and immunogenicity of high-dose pandemic H1N1 (pH1N1) vaccination in perinatally human immunodeficiency virus type 1 (HIV-1)-infected children, adolescents, and young adults are unknown. Methods: Two 30-μg doses...
9.
Mofenson L, Brady M, Danner S, Dominguez K, Hazra R, Handelsman E, et al.
MMWR Recomm Rep
. 2009 Sep;
58(RR-11):1-166.
PMID: 19730409
This report updates and combines into one document earlier versions of guidelines for preventing and treating opportunistic infections (OIs) among HIV-exposed and HIV-infected children, last published in 2002 and 2004,...
10.
Chantry C, Frederick M, Meyer 3rd W, Handelsman E, Rich K, Paul M, et al.
Pediatr Infect Dis J
. 2007 Jan;
26(1):53-60.
PMID: 17195707
Objectives: Identify endocrine differences between human immunodeficiency virus- (HIV) infected versus uninfected children and evaluate associations of growth and body composition with endocrine measures. Study Design: Nested case-control study in...